Bristol Myers Squibb Company $BMY Stock Holdings Lowered by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 70.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,042 shares of the biopharmaceutical company’s stock after selling 147,164 shares during the period. Pinnacle Financial Partners Inc’s holdings in Bristol Myers Squibb were worth $2,753,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Exchange Capital Management Inc. increased its stake in shares of Bristol Myers Squibb by 0.4% during the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after acquiring an additional 220 shares during the period. Parsons Capital Management Inc. RI grew its stake in shares of Bristol Myers Squibb by 0.3% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock worth $3,615,000 after purchasing an additional 224 shares during the last quarter. Richwood Investment Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 1.7% in the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock worth $616,000 after purchasing an additional 225 shares in the last quarter. Mccarter Private Wealth Services LLC lifted its stake in Bristol Myers Squibb by 5.0% during the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 235 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV boosted its holdings in Bristol Myers Squibb by 26.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 237 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMY. Morgan Stanley reiterated an “underweight” rating and set a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $56.86.

Bristol Myers Squibb Trading Down 2.3%

Shares of NYSE:BMY opened at $55.30 on Friday. The firm has a fifty day moving average of $51.91 and a two-hundred day moving average of $48.13. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The firm has a market capitalization of $112.58 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 9.15 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same period last year, the company earned $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.6%. Bristol Myers Squibb’s payout ratio is 85.14%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.